These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 23642372

  • 1. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema.
    Stein JD, Newman-Casey PA, Kim DD, Nwanyanwu KH, Johnson MW, Hutton DW.
    Ophthalmology; 2013 Sep; 120(9):1835-42. PubMed ID: 23642372
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
    Dewan V, Lambert D, Edler J, Kymes S, Apte RS.
    Ophthalmology; 2012 Aug; 119(8):1679-84. PubMed ID: 22503301
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema.
    Brown GC, Brown MM, Turpcu A, Rajput Y.
    Ophthalmology; 2015 Jul; 122(7):1416-25. PubMed ID: 25935787
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
    Hutton DW, Stein JD, Glassman AR, Bressler NM, Jampol LM, Sun JK, DRCR Retina Network.
    JAMA Ophthalmol; 2019 Dec 01; 137(12):1424-1432. PubMed ID: 31647496
    [Abstract] [Full Text] [Related]

  • 8. Clinical applications of cost analysis of diabetic macular edema treatments.
    Smiddy WE.
    Ophthalmology; 2012 Dec 01; 119(12):2558-62. PubMed ID: 23062655
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cost Evaluation of Early Vitrectomy versus Panretinal Photocoagulation and Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy.
    Lin J, Chang JS, Yannuzzi NA, Smiddy WE.
    Ophthalmology; 2018 Sep 01; 125(9):1393-1400. PubMed ID: 29606379
    [Abstract] [Full Text] [Related]

  • 14. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
    Patel JJ, Mendes MA, Bounthavong M, Christopher ML, Boggie D, Morreale AP.
    J Eval Clin Pract; 2012 Apr 01; 18(2):247-55. PubMed ID: 20846318
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cost Evaluation of Panretinal Photocoagulation versus Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy.
    Lin J, Chang JS, Smiddy WE.
    Ophthalmology; 2016 Sep 01; 123(9):1912-8. PubMed ID: 27425822
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial.
    Hutton DW, Stein JD, Bressler NM, Jampol LM, Browning D, Glassman AR, Diabetic Retinopathy Clinical Research Network.
    JAMA Ophthalmol; 2017 Jun 01; 135(6):576-584. PubMed ID: 28492920
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.